Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01052467

Enrollment

724

Registered

2010-01-20

Start date

2010-01-31

Completion date

2010-05-31

Last updated

2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Scalp Psoriasis

Brief summary

This non-interventional, prospective, non-controlled study of Xamiol® Gel, a fixed combination of calcipotriol and betamethason dipropionate, shall investigate in daily routine the efficacy, tolerability and changes in quality-of-life parameters in patients with scalp psoriasis

Interventions

DRUGXamiol® Gel

Once daily application for about 4 weeks

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with scalp psoriasis if a treatment with Xamiol® gel is planned anyway

Exclusion criteria

* Contraindications of Xamiol® Gel listed in the German package insert * Pretreatment with Xamiol® within the last 4 weeks * Systemic treatment of psoriasis * UV light therapy

Design outcomes

Primary

Measure	Time frame
Physician's Global Assessment of scalp psoriasis	After approximately 4 weeks

Secondary

Measure	Time frame
Patient's Quality of Life	After approximately 4 weeks

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026